| Thomas R. Cannell |
Presently, Thomas R. Cannell occupies the position of President, Chief Executive Officer & Director at Sesen Bio, Inc.
In his past career he held the position of General Manager at Merck & Co., Inc. President & Managing Director at Merck Canada, Inc. and Chief Marketing & Strategy Officer at MSD (Japan) Co., Ltd. (both are subsidiaries of Merck & Co., Inc.) and COO & President-Global Commercial Products at Orexigen Therapeutics, Inc.
Thomas R. Cannell received a doctorate and an undergraduate degree from Washington State University. |
| Minori Rosales |
Minori Rosales is Chief Development Officer at Sesen Bio, Inc.
Dr. Rosales previously was Vice President-Clinical Research at MacroGenics, Inc. and Vice President of MedImmune LLC.
She received a doctorate from Yamaguchi University and a doctorate from Kansai Medical University. |
| Monica Forbes |
Presently, Monica Forbes holds the position of Chief Financial Officer & Treasurer at Sesen Bio, Inc.
In her past career she was Chief Financial Officer & Vice President at Orexigen Therapeutics, Inc. and Chief Financial Officer & Vice President for Nalpropion Pharmaceuticals, Inc.
She received an undergraduate degree from San Diego State University. |
| John Knighton |
John Knighton is Chief Compliance Officer & Vice President at Sesen Bio, Inc. Dr. Knighton is also Member of State Bar of Georgia.
In the past he held the position of Chief Compliance Officer for TherapeuticsMD, Inc., Chief Compliance Officer of Wright Medical Group, Inc., Head-Global Compliance at Orexigen Therapeutics, Inc. and Chief Compliance Officer of MicroPort Orthopedics, Inc.
John Knighton received an undergraduate degree from Villanova University and a graduate degree from Emory University School of Law. |
| Kirstin N. Anderson |
Kirstin N. Anderson is Senior Director-Finance at Sesen Bio, Inc.
In the past she occupied the position of Chief Financial Officer at ClearStream Investments LLC, Staff Associate at Arthur Anderson & Co. and Audit Consultant at Deloitte & Touche LLP.
Kirstin N. Anderson received an undergraduate degree from the University of Maryland and a graduate degree from The University of Colorado. |
| Glen C. MacDonald |
Presently, Glen C. MacDonald holds the position of Chief Technology Officer of Sesen Bio, Inc. and President, CEO, CFO & Director at Leucadia Finance Partners, Inc.
In the past he occupied the position of Chief Scientific Officer at Viventia Biotech, Inc., Chief Scientific Officer for Viventia Bio, Inc., Principal at Princess Margaret Hospital Foundation and Principal at The University of North Carolina at Charlotte.
He received a doctorate and a graduate degree from the University of Manitoba and an undergraduate degree from the University of Guelph. |
| Elly Ryu |
Currently, Elly Ryu holds the position of Chief Accounting Officer & Controller at Sesen Bio, Inc.
Ms. Ryu previously occupied the position of Director-Accounting & Accounting at Spectrum Pharmaceuticals, Inc. and Director-Finance & Accounting at Acrotech Biopharma LLC.
She received an MBA from the University of California, Irvine and an undergraduate degree from Sogang University. |
| Jay S. Duker |
Founder of Hemera Biosciences, Inc., Jay S. Duker presently holds the position of Chairman at Sesen Bio, Inc. and President & Chief Operating Officer of EyePoint Pharmaceuticals, Inc. Dr. Duker is also on the board of Hemera Biosciences, Inc. and Chairman-Ophthalmology & Professor at Tufts University School of Medicine.
Dr. Duker previously occupied the position of Professor & Chairman-Ophthalmology Department at Tufts Medical Center, Inc.
Dr. Duker received a doctorate from Sidney Kimmel Medical College and an undergraduate degree from Harvard University. |
| Carrie L. Bourdow |
Carrie L. Bourdow is on the board of Sesen Bio, Inc. and Nabriva Therapeutics Plc and President, Chief Executive Officer & Director at Trevena, Inc.
In the past Ms. Bourdow held the position of Vice President-Marketing at Cubist Pharmaceuticals LLC.
Carrie L. Bourdow received an undergraduate degree from Hendrix College and an MBA from Southern Illinois University. |
| Michael A S Jewett |
Michael A S Jewett is on the board of Sesen Bio, Inc. and Professor at the University of Toronto and Professor at Princess Margaret Cancer Centre.
He received an undergraduate degree from Queen's University School of Medicine. |
| Peter K. Honig |
Peter K. Honig is Director-Drug Safety at Center for Drug Evaluation & Research and on the board of 7 other companies.
In the past Dr. Honig occupied the position of Member-Management Board at Medical Dictionary For Regulatory Activities, Senior VP-Worldwide Regulatory Affairs & Product S at Merck & Co., Inc., Senior VP & Head-Global Regulatory Affairs at Pfizer Inc., Director-Drug Safety at US Food & Drug Administration, Head-Global Regulatory Affairs & Patient Safety at AstraZeneca LP and President for The American Society for Clinical Pharmacology & Therapeutics.
He received a doctorate from Columbia University College of Physicians & Surgeons, a graduate degree from Joseph L. Mailman School of Public Health, an undergraduate degree from Columbia College (New York) and a graduate degree from The Trustees of Columbia University in The City of New York. |
| Jason A. Keyes |
Presently, Jason A. Keyes occupies the position of Chief Financial Officer at Equillium, Inc. Mr. Keyes is also on the board of Sesen Bio, Inc.
In the past Mr. Keyes held the position of Senior Director-Finance at Amylin Pharmaceuticals, Inc. and Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc.
Jason A. Keyes received a graduate degree and an undergraduate degree from Stanford University, an MBA from the University of California, Los Angeles and an MBA from UCLA Anderson School of Management. |
